<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-24552" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Lymphangioleiomyomatosis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Khaddour</surname>
            <given-names>Karam</given-names>
          </name>
          <aff>Rosalind Franklin University of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sankari</surname>
            <given-names>Abdulghani</given-names>
          </name>
          <aff>Wayne State University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Shayuk</surname>
            <given-names>Maryna</given-names>
          </name>
          <aff>Rosalind Franklin University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Karam Khaddour declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abdulghani Sankari declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Maryna Shayuk declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>11</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-24552.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Lymphangioleiomyomatosis (LAM) is a primary disease of the lung parenchyma caused by abnormal growth of smooth muscle cells in the lung vasculature, lymphatics, and alveoli that leads to the formation of multiple cysts in the lungs bilaterally and respiratory symptoms, such as dyspnea on exertion. The main involved organs are the lungs, but LAM can have extrapulmonary manifestations in the kidneys, causing benign renal angiomyolipomas, or can sometimes cause perivascular epithelioid cell tumors with visceral organ involvement. This activity reviews the pathophysiology, presentation, and diagnosis of lymphangioleiomyomatosis and highlights the role of the interprofessional team in its management.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the pathophysiology of lymphangioleiomyomatosis.</p></list-item><list-item><p>Review the presentation of a patient with lymphangioleiomyomatosis.</p></list-item><list-item><p>Summarize the treatment options for lymphangioleiomyomatosis.</p></list-item><list-item><p>Explain the importance of improving care coordination among interprofessional team members to improve outcomes for patients affected by lymphangioleiomyomatosis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24552&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24552">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-24552.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Lymphangioleiomyomatosis (LAM) is a primary disease of the lung parenchyma typified by abnormal growth of atypical smooth muscle cells in the lung vasculature, lymphatics, and alveoli that leads to the formation of multiple cysts in the lungs bilaterally causing respiratory symptoms, such as fatigue and dyspnea on exertion. The main involved organs are the lungs, but LAM can have extrapulmonary manifestations in the kidneys, causing benign renal angiomyolipomas, or can sometimes cause perivascular epithelioid cell tumors with visceral organ involvement. This article discusses the etiology, epidemiology,&#x000a0;clinical manifestations, and management options of LAM.&#x000a0;</p>
      </sec>
      <sec id="article-24552.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>LAM can present sporadically (S-LAM) or can be associated with tuberous sclerosis complex (TSC-LAM); however, pathologically, these two types are indistinguishable.<xref ref-type="bibr" rid="article-24552.r1">[1]</xref></p>
        <p>The etiology of LAM is not known; however, the genetic and hormonal etiologies have been recently elucidated based on the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>The disease is exacerbated by high estrogen states points towards a hormonal role.<xref ref-type="bibr" rid="article-24552.r2">[2]</xref><xref ref-type="bibr" rid="article-24552.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p>The genetic predisposition and various mutations have been linked to both types of LAM (S-LAM and SCL-LAM).&#x000a0;<xref ref-type="bibr" rid="article-24552.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>The sporadic form affects almost&#x000a0;only&#x000a0;premenopausal women, although some rare cases were reported to occur in men.<xref ref-type="bibr" rid="article-24552.r4">[4]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The most common type of LAM, TSC-LAM, is an autosomal dominant genetic disease and is considered the most common type of LAM.</p>
          </list-item>
          <list-item>
            <p>TSC genes function as tumor suppressor genes.&#x000a0;<italic toggle="yes">TSC1</italic>&#x000a0;encodes hamartin and&#x000a0;<italic toggle="yes">TSC2</italic>&#x000a0;encodes tuberin. These two key genes are linked to a complex called TBC1D7, which regulates&#x000a0;the kinase mechanistic target of the rapamycin (called mTOR).<xref ref-type="bibr" rid="article-24552.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>The mutations in the TSC genes, such as TSC2 mutation, have been linked to causing overactivation of the mTOR pathway&#x000a0;leading to defects in smooth muscle cell proliferation&#x000a0;and the formation of benign tumors&#x000a0;(angiomyolipomas) in multiple organs that are commonly seen in LAM.&#x000a0;<xref ref-type="bibr" rid="article-24552.r6">[6]</xref><xref ref-type="bibr" rid="article-24552.r7">[7]</xref>&#x000a0;The mTOR pathway is important for intracellular phosphorylation and extracellular signal-regulated kinase (ERK)&#x000a0;hence serving as a regulator for the growth and proliferation of cells. Thus, the targeted inhibition of the mTOR pathway plays a key role in the development of the new therapy for patients with TSC.<xref ref-type="bibr" rid="article-24552.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>Mutations in&#x000a0;<italic toggle="yes">TSC2</italic>&#x000a0;account for the majority (75%) of TSC cases.<xref ref-type="bibr" rid="article-24552.r8">[8]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24552.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The prevalence of S-LAM is unknown; however, one study&#x000a0;was done in 7 countries and estimated the prevalence of 3 to 7 cases per million in women.<xref ref-type="bibr" rid="article-24552.r9">[9]</xref>&#x000a0;Another study revealed that the sporadic form affects 1 in 400,000 adult women.<xref ref-type="bibr" rid="article-24552.r10">[10]</xref><xref ref-type="bibr" rid="article-24552.r5">[5]</xref>&#x000a0;The age of most commonly affected individuals is about 35 years old. LAM associated with TSC (TSC-LAM) is more common than S-LAM. One study&#x000a0;estimated the incidence to affect&#x000a0;1 in 5000 to 10,000 live births.<xref ref-type="bibr" rid="article-24552.r1">[1]</xref>&#x000a0;Patients with both tuberous sclerosis and&#x000a0;LAM are much more likely than others to develop angiomyolipomas which may occur in almost 90%&#x000a0;and&#x000a0;an overall&#x000a0;estimate of around&#x000a0;5 million women worldwide.<xref ref-type="bibr" rid="article-24552.r11">[11]</xref><xref ref-type="bibr" rid="article-24552.r12">[12]</xref>&#x000a0;The incidence rate increases with age, with the highest rates (as high as 80 %) among women&#x000a0;older than 40 years of age.<xref ref-type="bibr" rid="article-24552.r13">[13]</xref>&#x000a0;Unlike S-LAM, which occurs predominantly in women, TSC-LAM affects both men and women with TSC.&#x000a0;It is estimated that 10&#x000a0;to 30 % of men with TSC have cystic lung disease.<xref ref-type="bibr" rid="article-24552.r14">[14]</xref></p>
      </sec>
      <sec id="article-24552.s5" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Patients with LAM&#x000a0;can present&#x000a0;clinically with different manifestations.<xref ref-type="bibr" rid="article-24552.r5">[5]</xref><xref ref-type="bibr" rid="article-24552.r15">[15]</xref>&#x000a0;These include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>There can be the development of benign tumors in multiple organs&#x000a0;(brain, heart, skin, eyes, kidney, lung, and liver).</p>
          </list-item>
          <list-item>
            <p>LAM can present with acute respiratory manifestations during pregnancy or after the use of oral estrogen in females of reproductive age.</p>
          </list-item>
          <list-item>
            <p>Dyspnea is the most common presenting symptom that can occur during rest and increase with exertion. It could easily be mistaken and treated as a chronic obstructive pulmonary disease (COPD) or asthma. Progressive dyspnea and fatigue will be the initial symptom in about two-thirds of patients, one-third will present with spontaneous pneumothorax, and about a quarter will have a pleural effusion.<xref ref-type="bibr" rid="article-24552.r11">[11]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Lymphatic abnormalities (i.e., thoracic duct dilatation, chylothorax, and chylous ascites) are most common in TSC-LAM than in S-LAM.<xref ref-type="bibr" rid="article-24552.r16">[16]</xref></p>
          </list-item>
          <list-item>
            <p>Other less common manifestations include a productive cough, chest pain, pulmonary hypertension, and hemoptysis. Wheezing can be heard during physical examination in some patients.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Patients with TSC have skin lesions characteristic of the disorder (such as hypopigmented macules, forehead plaques, and facial&#x000a0;fibroadenomas) or defected nails (longitudinal nail grooves).</p>
          </list-item>
          <list-item>
            <p>Epilepsy and cognitive impairment are common in individuals with TSC.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Brain lesions such as cortical hamartomas (glioneuronal and subependymal), astrocytoma (a low-grade astrocytic brain tumor within the ventricles of the brain), and heterotopia (which as&#x000a0;ectopic collections of neurons). These brain lesions can be asymptomatic and detected radiologically or&#x000a0;present clinically as papilledema or hydrocephalus in patients with TSC.<xref ref-type="bibr" rid="article-24552.r17">[17]</xref></p>
          </list-item>
          <list-item>
            <p>LAM can be associated with renal angiomyolipomas (which are more frequent in TSC-LAM and often bilateral).&#x000a0;<xref ref-type="bibr" rid="article-24552.r18">[18]</xref></p>
          </list-item>
          <list-item>
            <p>TSC-LAM may be associated with polycystic kidney disease.<xref ref-type="bibr" rid="article-24552.r18">[18]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Pulmonary symptoms may worsen&#x000a0;during menses in a third of women with LAM. Likewise,&#x000a0;lung function has been reported to worsen after estrogen administration and during pregnancy.<xref ref-type="bibr" rid="article-24552.r5">[5]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24552.s6" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>
<bold>Laboratory Studies</bold>
</p>
        <p>Patients with lymphangioleiomyomatosis do not have an abnormal complete blood count (CBC) or comprehensive metabolic panel (CMP) unless they have other medical conditions.&#x000a0;No definitive tests or biomarkers can definitively establish the diagnosis of LAM. However, some studies suggest that measuring vascular endothelial growth factor D (VEGF-D) in patients suspected of LAM is reasonable as levels greater than or equal to 800 pg/mL have a high sensitivity and specificity for pulmonary lymphangioleiomyomatosis.<xref ref-type="bibr" rid="article-24552.r19">[19]</xref> Pleural effusions, if present, are usually chylomicron due to lymphatic obstruction from abnormal growth. Triglyceride levels are usually greater than 110 mg/dL.</p>
        <p>
<bold>Pulmonary Function Testing</bold>
</p>
        <p>Airflow obstruction is the most common presentation of LAM, but restrictive or mixed patterns&#x000a0;can also occur. Most patients with LAM have increased airflow resistance, reversible airflow obstruction, and obstructive pulmonary pattern. Therefore&#x000a0;they&#x000a0;are expected to have decreased FEV1/FVC and decreased DLCO on pulmonary function testing. Some reversibility can be noticed upon administering bronchodilators during testing, which is why some patients with respiratory symptoms could be diagnosed initially as having asthma. In clinical practice, a six-minute walk test can be used to assess for hypoxia and oxygen requirements in patients with LAM.</p>
        <p>
<bold>Imaging</bold>
</p>
        <p>Chest x-ray shows no specific findings in patients with LAM. The cystic disease is difficult to recognize on a plain chest X-ray, and it may see only non-specific findings of pneumothorax or pleural effusions if present. High-resolution computed tomography (HRCT) has high sensitivity and specificity in detecting the disease and has been suggested as a modality for screening patients suspected of having LAM (strong recommendation).<xref ref-type="bibr" rid="article-24552.r20">[20]</xref><xref ref-type="bibr" rid="article-24552.r21">[21]</xref>&#x000a0;The characteristic diagnostic finding in lymphangioleiomyomatosis is the presence of multiple (usually &#x0003e;10), thin-walled (0.1 to 2 mm thick), well-demarcated, bilateral, diffusely distributed pulmonary cysts on high-resolution computed tomography.<xref ref-type="bibr" rid="article-24552.r10">[10]</xref><xref ref-type="bibr" rid="article-24552.r16">[16]</xref>&#x000a0;</p>
        <p>Septal thickening may be seen; usually, there is no associated lymphadenopathy. However, as LAM progresses, reticulonodular opacities, pleural thickening, or hyperinflation can&#x000a0;be seen. In addition, focal ground-glass opacities can be found&#x000a0;due to the proliferation of smooth muscle cells, pulmonary hemorrhage, and lymphatic congestion. Other thoracic radiological findings could include&#x000a0;septal thickening, chylothorax, pericardial effusion, thoracic duct dilatation, and mediastinal lymph node enlargement.<xref ref-type="bibr" rid="article-24552.r5">[5]</xref></p>
        <p>Imaging of the kidneys is also strongly recommended due to the frequently associated finding of renal angiomyolipomas in patients with LAM. It is reported that 45% to 60% of all LAM patients will develop renal angiomyolipomas.<xref ref-type="bibr" rid="article-24552.r11">[11]</xref><xref ref-type="bibr" rid="article-24552.r22">[22]</xref><xref ref-type="bibr" rid="article-24552.r23">[23]</xref>&#x000a0;CT abdomen and pelvis are recommended to screen for lymphangioleiomyomas and angiomyolipomas.&#x000a0;</p>
        <p>A screening CT scan is recommended&#x000a0;if&#x000a0;women resenting with spontaneous pneumothorax during childbearing age,&#x000a0;recurrent pneumothorax, or bilateral pneumothorax, and the presence of TSC.&#x000a0;</p>
        <p>
<bold>Biopsy</bold>
</p>
        <p>Biopsy remains the gold standard for diagnosing LAM, where the characteristic abnormal smooth muscle-like cells can be seen under&#x000a0;microscopy. The best approach for biopsy is surgically through either video-assisted thoracoscopy, trans-bronchial lung biopsy, or surgical wedge resection. There are no guidelines&#x000a0;on the best approach for the biopsy. Trans-bronchial lung biopsy has a lower yield and higher false-negative rate than surgical biopsy. However, the decision is based on local experience, patient comorbidities, and wishes.&#x000a0;The diagnostic yield and safety of transbronchial lung biopsy and transbronchial cryobiopsy require further investigation.&#x000a0;</p>
        <p>
<bold>Pathology and use of biomarkers&#x000a0;</bold>
</p>
        <p>The characteristic pathological findings of pulmonary LAM are smooth muscle cell proliferation in the walls of the alveoli and vascular bed in lung tissue on a&#x000a0;hematoxylin-eosin stain (H and E) slide. Pathology can also show cystic spaces. The diagnosis is established by immunohistochemical staining, which will be positive for HMB-45, actin, myosin, estrogen, and progesterone.&#x000a0;There have been cases with a diagnosis of LAM through cytology by seeing the smooth muscle-like cells and positive stains, but this remains a low yield compared to tissue biopsy evaluations.<xref ref-type="bibr" rid="article-24552.r24">[24]</xref></p>
        <p>Traditionally to&#x000a0;confirm LAM diagnosis, a histopathological test after surgical lung biopsy&#x000a0;is required, but the diagnosis can be made clinically&#x000a0;through the presence of CT imaging and the presence&#x000a0;of one of the following: a diagnosis of TSC, a chylous effusion, lymphangioleiomyoma, renal angiomyolipoma or elevated VEGF-D (strong recommendation).<xref ref-type="bibr" rid="article-24552.r25">[25]</xref><xref ref-type="bibr" rid="article-24552.r5">[5]</xref>&#x000a0;The serum VEGF-D test has frequently eliminated&#x000a0;the need for biopsy as it has a very low false-positive rate and a high false-negative rate. At a threshold level of 800 pg/mL, the diagnostic threshold reported 100% specificity, which is currently used by&#x000a0;the College of American Pathologists/Clinical Laboratory Improvement Amendments laboratory.<xref ref-type="bibr" rid="article-24552.r26">[26]</xref> Thus the elevated VEGF-D level (&#x02265;800 pg/mL)&#x000a0;can be used to confirm LAM, but low levels (&#x0003c;800 pg/mL)&#x000a0;can&#x000a0;not exclude LAM.&#x000a0;</p>
      </sec>
      <sec id="article-24552.s7" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Management aims to control the symptoms, improve quality of life, and slow disease progression. In addition to medical treatment, supportive care includes smoking cessation and correction of hypoxia with adequate O2 supplementation. The management approach outlined here&#x000a0;is evidence-based recommendations according to&#x000a0;the American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines.&#x000a0;<xref ref-type="bibr" rid="article-24552.r25">[25]</xref></p>
        <p>
<bold>Bronchodilators</bold>
</p>
        <p>Bronchodilators are used for symptomatic control and relief of symptoms in patients who show reversibility on PFTs. Usually, beta-agonists and anticholinergics are used in the treatment. Studies have shown the benefit and reversibility of airflow obstruction in patients with LAM treated with albuterol and ipratropium after adjusting for smoking and asthmatic status.<xref ref-type="bibr" rid="article-24552.r27">[27]</xref></p>
        <p>
<bold>Respiratory Rehabilitation</bold>
</p>
        <p>Studies have shown that respiratory rehabilitation in patients with decreased functional capacity and respiratory symptoms benefits from it. It encourages all healthcare professionals to consider patients with LAM to have respiratory rehabilitation to increase endurance and improve their quality of life.<xref ref-type="bibr" rid="article-24552.r28">[28]</xref></p>
        <p>
<bold>Medication</bold>
</p>
        <p>Sirolimus is approved&#x000a0;to treat LAM by the US Food and Drug Administration (FDA), the European Medicines Agency, and drug agencies in other countries. Sirolimus is an (mTOR) inhibitor that controls the abnormal proliferation and growth of smooth muscle cells in the lung parenchyma and is effective and safe. The medication has shown in the MILES trial&#x000a0;the ability to prevent the worsening of lung function (stabilization of FEV&#x000a0;and improvement in FVC) and respiratory symptoms while improving the quality of life and reducing serum VEGF-D levels.<xref ref-type="bibr" rid="article-24552.r29">[29]</xref>&#x000a0;The recommended initial dose of sirolimus is 1 mg orally once daily and titration to 2 to maintain a trough&#x000a0;level &#x02264;10&#x000a0;ng/mL (usually after the first week of initiating treatment). The adverse effects of sirolimus are reported to occur in the first few months of initiation of therapy, which are generally dose-related.<xref ref-type="bibr" rid="article-24552.r30">[30]</xref>&#x000a0;These side effects include diarrhea, stomatitis, dyspepsia, nausea, hypercholesterolemia, and acneiform rash. Other uncommon adverse events include lower extremity edema, renal failure, infection, delayed wound healing, pneumonitis, allergic reaction, and anemia.<xref ref-type="bibr" rid="article-24552.r31">[31]</xref></p>
        <p>Sirolimus can alleviate the lymphatic manifestations of LAM, such as chylous effusions and lymphangioleiomyomas. Sirolimus is considered the first-line treatment for symptomatic patients with LAM with one of the following criteria (strong recommendation): FEV1&#x000a0; &#x0003c;70% of predicted, chylous complications, and rapidly progressive disease such as FEV1 decline &#x02265;90 mL per year, or problematic chylous accumulations. The safety profile of sirolimus is reasonable and includes nonspecific symptoms such as nausea, diarrhea, mucositis, acne, lower-extremity swelling, and hyperlipidemia.<xref ref-type="bibr" rid="article-24552.r25">[25]</xref></p>
        <p>Everolimus is an alternative for patients who cannot tolerate sirolimus or have allergies, but the FDA has not approved it for this purpose, and its use is still off-label. However, everolimus has approval for treating AMLs, central nervous system tumors, and epilepsy due to TSC and renal angiomyolipomas in LAM patients, particularly when associated with tuberous sclerosis.<xref ref-type="bibr" rid="article-24552.r32">[32]</xref><xref ref-type="bibr" rid="article-24552.r33">[33]</xref><xref ref-type="bibr" rid="article-24552.r34">[34]</xref></p>
        <p>Hormonal modulating therapy has been hypothesized to be an option for treatment, given the role of estrogen. Selective estrogen receptor modulators could play a role in treating the disease. However, there have been no clinical trials assessing the efficacy of these medications. One study assesses the safety of letrozole in postmenopausal women with LAM, but the study did not conclude with accurate results, given the approval of the sirolimus when the letrozole study was recruiting patients. The use of anti-estrogen treatments is not recommended outside of the clinical trial or investigation; hence hormonal therapy is not recommended treatment for LAM (conditional recommendation). Another treatment, such as doxycycline, is&#x000a0;not recommended due to weak evidence (conditional recommendation).<xref ref-type="bibr" rid="article-24552.r25">[25]</xref></p>
        <p>
<bold>Lung Transplantation</bold>
</p>
        <p>Lung transplantation remains the best option for a patient who progresses with worsening symptoms and lung function despite supportive and refractory treatment with an mTOR inhibitor. However, many anecdotal case reports mentioned recurrence with LAM after lung transplantation, raising a question about the curative role of this surgical treatment modality.</p>
        <p>
<bold>Pleurodesis</bold>
</p>
        <p>In refractory cases of pneumothorax related to LAM, chemical pleurodesis using talc&#x000a0;is recommended. Due to the potential delay in wound healing associated with sirolimus, it is usually recommended to stop the drug&#x000a0; 2&#x000a0;to 4 weeks after the resolution of pneumothorax.&#x000a0;</p>
      </sec>
      <sec id="article-24552.s8" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Following are some important differentials of lymphangioleiomyomatosis:</p>
        <list list-type="bullet">
          <list-item>
            <p>Amyloidosis</p>
          </list-item>
          <list-item>
            <p>Asthma</p>
          </list-item>
          <list-item>
            <p>Benign metastasizing myeloma</p>
          </list-item>
          <list-item>
            <p>Birt-Hogg-Dube syndrome</p>
          </list-item>
          <list-item>
            <p>Diffuse pulmonary lymphangiomyosis</p>
          </list-item>
          <list-item>
            <p>Emphysema</p>
          </list-item>
          <list-item>
            <p>Eosinophilic granuloma</p>
          </list-item>
          <list-item>
            <p>Follicular bronchiolitis</p>
          </list-item>
          <list-item>
            <p>Interstitial myofibrosis</p>
          </list-item>
          <list-item>
            <p>Leiomyosarcoma</p>
          </list-item>
          <list-item>
            <p>Lymphoid interstitial pneumonia</p>
          </list-item>
          <list-item>
            <p>Light-chain deposition disease</p>
          </list-item>
          <list-item>
            <p>Pulmonary Langerhans cell histiocytosis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24552.s9" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Now the&#x000a0;mortality is found to be longer than what has been reported in the previous decade. The median transplant-free survival in patients with LAM is estimated to be 29 years from symptom onset and 23 years from diagnosis.<xref ref-type="bibr" rid="article-24552.r35">[35]</xref> Given the possibility of recurrence after lung transplantation, many experts now consider the disease to be a low-grade neoplasm. Pleural disease and pneumothorax in LAM are refractory and can recur even after pleurodesis is performed in a third of cases.<xref ref-type="bibr" rid="article-24552.r36">[36]</xref><xref ref-type="bibr" rid="article-24552.r5">[5]</xref>&#x000a0;</p>
        <p>Due to the potential of pressure changes associated with air travel, there is an increased risk of pulmonary cysts rupture and&#x000a0;spontaneous pneumothorax in patients with LAM. Therefore,&#x000a0;patients should be counseled about air travel-associated risks and the possible need for inflight oxygen supplements.<xref ref-type="bibr" rid="article-24552.r5">[5]</xref><xref ref-type="bibr" rid="article-24552.r36">[36]</xref></p>
      </sec>
      <sec id="article-24552.s10" sec-type="Complications">
        <title>Complications</title>
        <p>All patients with&#x000a0;lymphangioleiomyomatosis should be advised to avoid using estrogen-containing oral contraceptive pills, given the increased rate of worsening symptoms with their use. Progesterone-based oral contraceptives appear to be safe and could be an alternative. Pregnancy can also increase the risk of worsening symptoms and complications, but patients with LAM reported having multiple pregnancies without complications. Patients with LAM should receive influenza and pneumococcal vaccination.&#x000a0;</p>
      </sec>
      <sec id="article-24552.s11" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients of lymphangioleiomyomatosis and their families should be made aware of the management plan and complications associated with the disease. They should be given information about the prognosis and treatment options.&#x000a0;Counseling for&#x000a0;women&#x000a0;with LAM who are considering becoming pregnant should be&#x000a0;performed about&#x000a0;potential risks,&#x000a0;and usually&#x000a0;depend on factors such as the pulmonary reserves of the mother.<xref ref-type="bibr" rid="article-24552.r37">[37]</xref>&#x000a0;In addition, women should be counseled about avoiding estrogen-containing medications and contraceptives, and patients should be informed about the increased risks of LAM progression associated with pregnancy.</p>
      </sec>
      <sec id="article-24552.s12" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Awareness of the possible complications and drug influence in this condition is a key concept in diagnosing and treating lymphangioleiomyomatosis.&#x000a0;Improving&#x000a0;care coordination among interprofessional team members is crucial to improve outcomes for patients affected by lymphangioleiomyomatosis.&#x000a0;</p>
        <p>Clinicians (MDs, DOs, NPs, and PAs) will direct the overall treatment and management of&#x000a0;lymphangioleiomyomatosis, but it requires the efforts of an interprofessional team that also includes specialists, nursing staff, pharmacists, and respiratory therapists to successfully manage the case. Open communication among all team members is crucial to success, and all professionals involved in care must document every intervention or interaction with the patient so that everyone on the team has access to the same accurate, updated patient data. The interprofessional model will yield optimal patient results with the fewest complications. [Level 5]</p>
      </sec>
      <sec id="article-24552.s13">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24552&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24552">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/lung-disease-respiratory-health/lymphangioleiomyomatosis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=24552">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/24552/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=24552">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-24552.s14">
        <title>References</title>
        <ref id="article-24552.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Northrup</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Aronow</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Bebin</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Bissler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Darling</surname>
                <given-names>TN</given-names>
              </name>
              <name>
                <surname>de Vries</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Frost</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Fuchs</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Gosnell</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Jansen</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>J&#x000f3;&#x0017a;wiak</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kingswood</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Knilans</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>McCormack</surname>
                <given-names>FX</given-names>
              </name>
              <name>
                <surname>Pounders</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Roberds</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Rodriguez-Buritica</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Roth</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sampson</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Sparagana</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Thiele</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Weiner</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Wheless</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Towbin</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Krueger</surname>
                <given-names>DA</given-names>
              </name>
              <collab>International Tuberous Sclerosis Complex Consensus Group</collab>
            </person-group>
            <article-title>Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations.</article-title>
            <source>Pediatr Neurol</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>123</volume>
            <fpage>50</fpage>
            <page-range>50-66</page-range>
            <pub-id pub-id-type="pmid">34399110</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24552.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shaw</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Kopras</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Menstrual Cycle-related Respiratory Symptom Variability in Patients with Lymphangioleiomyomatosis.</article-title>
            <source>Ann Am Thorac Soc</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>19</volume>
            <issue>9</issue>
            <fpage>1619</fpage>
            <page-range>1619-1621</page-range>
            <pub-id pub-id-type="pmid">35649208</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24552.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Tian</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>KF</given-names>
              </name>
            </person-group>
            <article-title>Gene mutations in sporadic lymphangioleiomyomatosis and genotype-phenotype correlation analysis.</article-title>
            <source>BMC Pulm Med</source>
            <year>2022</year>
            <month>Sep</month>
            <day>18</day>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>354</fpage>
            <pub-id pub-id-type="pmid">36117164</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24552.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wakida</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kumasaka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Seyama</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mitani</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hiraki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kamimura</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nagata</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Lymphangioleiomyomatosis in a Male.</article-title>
            <source>Ann Thorac Surg</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>100</volume>
            <issue>3</issue>
            <fpage>1105</fpage>
            <page-range>1105-7</page-range>
            <pub-id pub-id-type="pmid">26354644</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24552.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCarthy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>McCormack</surname>
                <given-names>FX</given-names>
              </name>
            </person-group>
            <article-title>Lymphangioleiomyomatosis: pathogenesis, clinical features, diagnosis, and management.</article-title>
            <source>Lancet Respir Med</source>
            <year>2021</year>
            <month>Nov</month>
            <volume>9</volume>
            <issue>11</issue>
            <fpage>1313</fpage>
            <page-range>1313-1327</page-range>
            <pub-id pub-id-type="pmid">34461049</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24552.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Muzykewicz</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Muse</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Numis</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Rajagopal</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Thiele</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>TSC1 and TSC2 mutations in patients with lymphangioleiomyomatosis and tuberous sclerosis complex.</article-title>
            <source>J Med Genet</source>
            <year>2009</year>
            <month>Jul</month>
            <volume>46</volume>
            <issue>7</issue>
            <fpage>465</fpage>
            <page-range>465-8</page-range>
            <pub-id pub-id-type="pmid">19419980</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24552.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Curatolo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Specchio</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Aronica</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Advances in the genetics and neuropathology of tuberous sclerosis complex: edging closer to targeted therapy.</article-title>
            <source>Lancet Neurol</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>21</volume>
            <issue>9</issue>
            <fpage>843</fpage>
            <page-range>843-856</page-range>
            <pub-id pub-id-type="pmid">35963265</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24552.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tyburczy</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Dies</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Glass</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Camposano</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chekaluk</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Thorner</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Krueger</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Franz</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Thiele</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Sahin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kwiatkowski</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Mosaic and Intronic Mutations in TSC1/TSC2 Explain the Majority of TSC Patients with No Mutation Identified by Conventional Testing.</article-title>
            <source>PLoS Genet</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>11</volume>
            <issue>11</issue>
            <fpage>e1005637</fpage>
            <pub-id pub-id-type="pmid">26540169</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24552.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harknett</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>WY</given-names>
              </name>
              <name>
                <surname>Byrnes</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lazor</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Gray</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Geiling</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Telford</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tattersfield</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Hubbard</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Use of variability in national and regional data to estimate the prevalence of lymphangioleiomyomatosis.</article-title>
            <source>QJM</source>
            <year>2011</year>
            <month>Nov</month>
            <volume>104</volume>
            <issue>11</issue>
            <fpage>971</fpage>
            <page-range>971-9</page-range>
            <pub-id pub-id-type="pmid">21764810</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24552.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johnson</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Cordier</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Lazor</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cottin</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Costabel</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Harari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Reynaud-Gaubert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Boehler</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brauner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Popper</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bonetti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kingswood</surname>
                <given-names>C</given-names>
              </name>
              <collab>Review Panel of the ERS LAM Task Force</collab>
            </person-group>
            <article-title>European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis.</article-title>
            <source>Eur Respir J</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>35</volume>
            <issue>1</issue>
            <fpage>14</fpage>
            <page-range>14-26</page-range>
            <pub-id pub-id-type="pmid">20044458</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24552.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ryu</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Moss</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Beck</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Finlay</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Olson</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Ruoss</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Maurer</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Raffin</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Peavy</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>McCarthy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Taveira-Dasilva</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McCormack</surname>
                <given-names>FX</given-names>
              </name>
              <name>
                <surname>Avila</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Decastro</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Stylianou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fanburg</surname>
                <given-names>BL</given-names>
              </name>
              <collab>NHLBI LAM Registry Group</collab>
            </person-group>
            <article-title>The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2006</year>
            <month>Jan</month>
            <day>01</day>
            <volume>173</volume>
            <issue>1</issue>
            <fpage>105</fpage>
            <page-range>105-11</page-range>
            <pub-id pub-id-type="pmid">16210669</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24552.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johnson</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Tattersfield</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>Clinical experience of lymphangioleiomyomatosis in the UK.</article-title>
            <source>Thorax</source>
            <year>2000</year>
            <month>Dec</month>
            <volume>55</volume>
            <issue>12</issue>
            <fpage>1052</fpage>
            <page-range>1052-7</page-range>
            <pub-id pub-id-type="pmid">11083892</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24552.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cudzilo</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Szczesniak</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Brody</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Rattan</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Krueger</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Bissler</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Franz</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>McCormack</surname>
                <given-names>FX</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>LR</given-names>
              </name>
            </person-group>
            <article-title>Lymphangioleiomyomatosis screening in women with tuberous sclerosis.</article-title>
            <source>Chest</source>
            <year>2013</year>
            <month>Aug</month>
            <volume>144</volume>
            <issue>2</issue>
            <fpage>578</fpage>
            <page-range>578-585</page-range>
            <pub-id pub-id-type="pmid">23539171</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24552.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kristof</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Zhi Li</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Major</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Landry</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Lymphangioleiomyomatosis and Tuberous Sclerosis Complex in Quebec: Prevalence and Health-care Utilization.</article-title>
            <source>Chest</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>148</volume>
            <issue>2</issue>
            <fpage>444</fpage>
            <page-range>444-449</page-range>
            <pub-id pub-id-type="pmid">25789699</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24552.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carel</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Breathlessness: the rift between objective measurement and subjective experience.</article-title>
            <source>Lancet Respir Med</source>
            <year>2018</year>
            <month>May</month>
            <volume>6</volume>
            <issue>5</issue>
            <fpage>332</fpage>
            <page-range>332-333</page-range>
            <pub-id pub-id-type="pmid">29523434</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24552.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tobino</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Johkoh</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fujimoto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sakai</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Arakawa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kurihara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kumasaka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Koike</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Seyama</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Computed tomographic features of lymphangioleiomyomatosis: evaluation in 138 patients.</article-title>
            <source>Eur J Radiol</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>84</volume>
            <issue>3</issue>
            <fpage>534</fpage>
            <page-range>534-541</page-range>
            <pub-id pub-id-type="pmid">25544557</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24552.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wei</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Hsiao</surname>
                <given-names>YP</given-names>
              </name>
              <name>
                <surname>Gau</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>YT</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>The Efficacy of Everolimus for Facial Angiofibromas in Tuberous Sclerosis Complex Patients Treated for Renal Angiomyolipoma/Subependymal Giant Cell Astrocytoma.</article-title>
            <source>Dermatology</source>
            <year>2021</year>
            <volume>237</volume>
            <issue>3</issue>
            <fpage>444</fpage>
            <page-range>444-449</page-range>
            <pub-id pub-id-type="pmid">33032292</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24552.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kingswood</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Belousova</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Benedik</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cottin</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Curatolo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dahlin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>D'Amato</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Beaure d'Aug&#x000e8;res</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>de Vries</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Feucht</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fladrowski</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hertzberg</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jozwiak</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lawson</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Macaya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marques</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nabbout</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>O'Callaghan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Qin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sander</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Touraine</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Youroukos</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zonnenberg</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jansen</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Sauter</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Renal Manifestations of Tuberous Sclerosis Complex: Key Findings From the Final Analysis of the TOSCA Study Focussing Mainly on Renal Angiomyolipomas.</article-title>
            <source>Front Neurol</source>
            <year>2020</year>
            <volume>11</volume>
            <fpage>972</fpage>
            <pub-id pub-id-type="pmid">33041968</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24552.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chang</surname>
                <given-names>WY</given-names>
              </name>
              <name>
                <surname>Cane</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Blakey</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Kumaran</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pointon</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Clinical utility of diagnostic guidelines and putative biomarkers in lymphangioleiomyomatosis.</article-title>
            <source>Respir Res</source>
            <year>2012</year>
            <month>Apr</month>
            <day>18</day>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>34</fpage>
            <pub-id pub-id-type="pmid">22513045</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24552.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hagaman</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Schauer</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>McCormack</surname>
                <given-names>FX</given-names>
              </name>
              <name>
                <surname>Kinder</surname>
                <given-names>BW</given-names>
              </name>
            </person-group>
            <article-title>Screening for lymphangioleiomyomatosis by high-resolution computed tomography in young, nonsmoking women presenting with spontaneous pneumothorax is cost-effective.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2010</year>
            <month>Jun</month>
            <day>15</day>
            <volume>181</volume>
            <issue>12</issue>
            <fpage>1376</fpage>
            <page-range>1376-82</page-range>
            <pub-id pub-id-type="pmid">20167846</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24552.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Finlay</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Kotloff</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Strange</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Taveira-DaSilva</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Cottin</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sahn</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Ryu</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Seyama</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Inoue</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Downey</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Colby</surname>
                <given-names>TV</given-names>
              </name>
              <name>
                <surname>Wikenheiser-Brokamp</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Moss</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McCormack</surname>
                <given-names>FX</given-names>
              </name>
              <collab>ATS Assembly on Clinical Problems</collab>
            </person-group>
            <article-title>Lymphangioleiomyomatosis Diagnosis and Management: High-Resolution Chest Computed Tomography, Transbronchial Lung Biopsy, and Pleural Disease Management. An Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guideline.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2017</year>
            <month>Nov</month>
            <day>15</day>
            <volume>196</volume>
            <issue>10</issue>
            <fpage>1337</fpage>
            <page-range>1337-1348</page-range>
            <pub-id pub-id-type="pmid">29140122</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24552.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blute</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>How common are renal angiomyolipomas in patients with pulmonary lymphangiomyomatosis?</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>1996</year>
            <month>Nov</month>
            <volume>154</volume>
            <issue>5</issue>
            <fpage>1580</fpage>
            <page-range>1580-1</page-range>
            <pub-id pub-id-type="pmid">8912787</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24552.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Engels</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Stauber</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Magnussen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kirsten</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Watz</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wirtz</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Angiomyolipomas are indicator lesions for sporadic lymphangioleiomyomatosis in women.</article-title>
            <source>Eur Urol</source>
            <year>2009</year>
            <month>Mar</month>
            <volume>55</volume>
            <issue>3</issue>
            <fpage>755</fpage>
            <page-range>755-6</page-range>
            <pub-id pub-id-type="pmid">18835088</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24552.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rivera</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gokaslan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kurian</surname>
                <given-names>EM</given-names>
              </name>
            </person-group>
            <article-title>Lymphangioleiomyomatosis diagnosed by effusion cytology: A case report.</article-title>
            <source>J Cytol</source>
            <year>2015</year>
            <season>Oct-Dec</season>
            <volume>32</volume>
            <issue>4</issue>
            <fpage>287</fpage>
            <page-range>287-9</page-range>
            <pub-id pub-id-type="pmid">26811583</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24552.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCormack</surname>
                <given-names>FX</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Finlay</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Taveira-DaSilva</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Glasgow</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Steagall</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Sahn</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Ryu</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Strange</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Seyama</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Kotloff</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Downey</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>D'Armiento</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Inoue</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Henske</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Bissler</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Colby</surname>
                <given-names>TV</given-names>
              </name>
              <name>
                <surname>Kinder</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Wikenheiser-Brokamp</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Cordier</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cottin</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Brozek</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Moss</surname>
                <given-names>J</given-names>
              </name>
              <collab>ATS/JRS Committee on Lymphangioleiomyomatosis</collab>
            </person-group>
            <article-title>Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2016</year>
            <month>Sep</month>
            <day>15</day>
            <volume>194</volume>
            <issue>6</issue>
            <fpage>748</fpage>
            <page-range>748-61</page-range>
            <pub-id pub-id-type="pmid">27628078</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24552.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Young</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Vandyke</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gulleman</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Inoue</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Linehan</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Hajjar</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kinder</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Trapnell</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Bissler</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Franz</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>McCormack</surname>
                <given-names>FX</given-names>
              </name>
            </person-group>
            <article-title>Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases.</article-title>
            <source>Chest</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>138</volume>
            <issue>3</issue>
            <fpage>674</fpage>
            <page-range>674-81</page-range>
            <pub-id pub-id-type="pmid">20382711</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24552.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taveira-DaSilva</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Steagall</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Rabel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hathaway</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Harari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cassandro</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Stylianou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Moss</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Reversible airflow obstruction in lymphangioleiomyomatosis.</article-title>
            <source>Chest</source>
            <year>2009</year>
            <month>Dec</month>
            <volume>136</volume>
            <issue>6</issue>
            <fpage>1596</fpage>
            <page-range>1596-1603</page-range>
            <pub-id pub-id-type="pmid">19447921</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24552.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Araujo</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Baldi</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Freitas</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Albuquerque</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Marques da Silva</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Kairalla</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Carvalho</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Carvalho</surname>
                <given-names>CR</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary rehabilitation in lymphangioleiomyomatosis: a controlled clinical trial.</article-title>
            <source>Eur Respir J</source>
            <year>2016</year>
            <month>May</month>
            <volume>47</volume>
            <issue>5</issue>
            <fpage>1452</fpage>
            <page-range>1452-60</page-range>
            <pub-id pub-id-type="pmid">26917604</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24552.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCormack</surname>
                <given-names>FX</given-names>
              </name>
              <name>
                <surname>Inoue</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Moss</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Singer</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Strange</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nakata</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Barker</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Brantly</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Stocks</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Lynch</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Kinder</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Downey</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Colby</surname>
                <given-names>TV</given-names>
              </name>
              <name>
                <surname>McKay</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Korbee</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Taveira-DaSilva</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Krischer</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Trapnell</surname>
                <given-names>BC</given-names>
              </name>
              <collab>National Institutes of Health Rare Lung Diseases Consortium</collab>
              <collab>MILES Trial Group</collab>
            </person-group>
            <article-title>Efficacy and safety of sirolimus in lymphangioleiomyomatosis.</article-title>
            <source>N Engl J Med</source>
            <year>2011</year>
            <month>Apr</month>
            <day>28</day>
            <volume>364</volume>
            <issue>17</issue>
            <fpage>1595</fpage>
            <page-range>1595-606</page-range>
            <pub-id pub-id-type="pmid">21410393</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24552.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Neurohr</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hoffmann</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Huppmann</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Herrera</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Ihle</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Leuschner</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>von Wulffen</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Meis</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Baezner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Leuchte</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Baumgartner</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zimmermann</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Behr</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Is sirolimus a therapeutic option for patients with progressive pulmonary lymphangioleiomyomatosis?</article-title>
            <source>Respir Res</source>
            <year>2011</year>
            <month>May</month>
            <day>21</day>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>66</fpage>
            <pub-id pub-id-type="pmid">21600034</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24552.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Strange</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Moss</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Singer</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Nakata</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Barker</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Brantly</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Stocks</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Lynch</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Downey</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Taveira-DaSilva</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Krischer</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Setchell</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Trapnell</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Inoue</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>McCormack</surname>
                <given-names>FX</given-names>
              </name>
              <collab>NIH Rare Lung Disease Consortium</collab>
            </person-group>
            <article-title>Analysis of the MILES cohort reveals determinants of disease progression and&#x000a0;treatment response in lymphangioleiomyomatosis.</article-title>
            <source>Eur Respir J</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>53</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">30846465</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24552.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Xiang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ji</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>The efficacy and safety of pharmacological treatments for lymphangioleiomyomatosis.</article-title>
            <source>Respir Res</source>
            <year>2020</year>
            <month>Feb</month>
            <day>14</day>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>55</fpage>
            <pub-id pub-id-type="pmid">32059669</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24552.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bissler</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Nonomura</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Budde</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zonnenberg</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Fischereder</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Voi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Louveau</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Herbst</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bebin</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Curatolo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zonta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Belousova</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis.</article-title>
            <source>PLoS One</source>
            <year>2018</year>
            <volume>13</volume>
            <issue>9</issue>
            <fpage>e0201005</fpage>
            <pub-id pub-id-type="pmid">30192751</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24552.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Budde</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zonnenberg</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Frost</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cheung</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Urva</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Brechenmacher</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kingswood</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Bissler</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics and pharmacodynamics of everolimus in patients with renal angiomyolipoma and tuberous sclerosis complex or lymphangioleiomyomatosis.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2016</year>
            <month>May</month>
            <volume>81</volume>
            <issue>5</issue>
            <fpage>958</fpage>
            <page-range>958-70</page-range>
            <pub-id pub-id-type="pmid">26580489</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24552.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oprescu</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>McCormack</surname>
                <given-names>FX</given-names>
              </name>
              <name>
                <surname>Byrnes</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kinder</surname>
                <given-names>BW</given-names>
              </name>
            </person-group>
            <article-title>Clinical predictors of mortality and cause of death in lymphangioleiomyomatosis: a population-based registry.</article-title>
            <source>Lung</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>191</volume>
            <issue>1</issue>
            <fpage>35</fpage>
            <page-range>35-42</page-range>
            <pub-id pub-id-type="pmid">23007140</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24552.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Almoosa</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Ryu</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Mendez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Huggins</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Maurer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McCormack</surname>
                <given-names>FX</given-names>
              </name>
              <name>
                <surname>Sahn</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Management of pneumothorax in lymphangioleiomyomatosis: effects on recurrence and lung transplantation complications.</article-title>
            <source>Chest</source>
            <year>2006</year>
            <month>May</month>
            <volume>129</volume>
            <issue>5</issue>
            <fpage>1274</fpage>
            <page-range>1274-81</page-range>
            <pub-id pub-id-type="pmid">16685019</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24552.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Moss</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McCormack</surname>
                <given-names>FX</given-names>
              </name>
            </person-group>
            <article-title>Reply to Yanagisawa: Treatment of Pulmonary Lymphangioleiomyomatosis during Pregnancy.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2018</year>
            <month>Jun</month>
            <day>01</day>
            <volume>197</volume>
            <issue>11</issue>
            <fpage>1507</fpage>
            <page-range>1507-1508</page-range>
            <pub-id pub-id-type="pmid">29356560</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
